“The Whole HIV Patient” REYATAZ Campaign
After the global launch of Bristol-Myers Squibb’s revolutionary HIV protease inhibitor, REYATAZ, HLG was challenged with communicating the breadth of REYATAZ-appropriate patient types while continuing to emphasize the importance of patient quality of life. “The Whole HIV Patient” campaign featured a variety of different HIV patients in workplace scenarios to stress that, due to once-daily dosing and a favorable side effect profile, REYATAZ patients could carry out normal everyday activities while maintaining effective HIV therapy.
“The Whole HIV Patient” REYATAZ Campaign (continued)
An additional REYATAZ patient type featured as part of “The Whole HIV Patient” campaign (see previous creative example for more information).
SUSTIVA HIV Patient Profile Tablet Program
A non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, Bristol-Myers Squibb’s SUSTIVA had a wealth of real-life patient case studies demonstrating the proven power of this leading HIV therapy. This electronic, tablet-based patient profile program enabled the SUSTIVA sales force to detail a variety of different SUSTIVA success stories in an interactive and compelling format.
“The KALETRA Patient” Campaign
Known for its efficacy, Abbott’s HIV protease inhibitor, KALETRA, also offers patient-friendly advantages over other HIV therapies. As part of “The KALETRA Patient” campaign, this detail piece was created to identify KALETRA-appropriate patients while emphasizing this therapy’s commitment to its patients and their needs.
- REYATAZ (Global Launch)
- VIDEX EC